Half the standard dose of tissue plasminogen activator for pulmonary embolism exhibits similar efficacy and perhaps better safety in patients with acute pulmonary embolism.
Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low-dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137:254–262.